explore -WSS

explore

author：fashion 2025-09-06 03:53:53 - browse：83

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： $1 billion proposal to grow Boston, Massachusetts biotech

WSS

Change Healthcare: What is it, why does its cyberattack matter?

California’s proposed $25 per hour health care minimum wage

Iowa House, Senate pass 6

$1 billion proposal to grow Boston, Massachusetts biotech

Fetal cell organoids grown from amniotic fluid, study finds

Pregnant women don't need prenatal multivitamins, study concludes

knowledge

explore

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

$1 billion proposal to grow Boston, Massachusetts biotech

Cancer drug shortages should be causing more outrage

Biden's 'march

Trump demands the U.S. pay no more for drugs than other countries … again

Palantir health business leans on meeting customers’ needs

How one medical school became remarkably diverse

Leqembi, other new Alzheimer’s drugs require better biomarkers

Heart attack and stroke risk calculators need revising

Elizabeth Holmes on track for early release from her 11

leisure time

NIH fellows want a pay raise. Will that mean less money for grants?

Iowa House, Senate pass 6

Microsoft's Peter Lee: Generative AI could help doctors be more human

Study: Pain burden is higher in Black NFL players than white ones

Longer MASH drug regimen improved liver, Akero study finds

Study: Pain burden is higher in Black NFL players than white ones

focus

focus

entertainment

hotspot